Background: It has been hypothesized that the etiology of schizophrenia, in a distinct group of patients, originates from an autoimmune reaction against platelets. Previous open screenings have recorded significantly higher blood titers of platelet-associated autoantibodies (PAA) in schizophrenic patients as compared to normal healthy subjects. In addition, young schizophrenic patients at the early stages of their disorder displayed higher PAA titers than older patients with a longer duration of the disorder. A blood test based on these observations was proposed.
Aim: To verify by a blind test a significant difference in PAA between young schizophrenic patients and matched healthy control subjects, for the validation of a blood test for schizophrenia.
Methods: A total of 36 young schizophrenic patients in an active psychotic state, aged 13-20 years (mean +/- SD: 16.2 +/- 2.1 years) with an average PANSS score of 115.6 +/- 14.5 and illness duration of 9.5 +/- 9.4 months, were examined. The control group consisted of 49 healthy young subjects between the ages of 13 and 21 years (16.2 +/- 2.2 years). The blood titers of PAA were evaluated blindly using an optimized ELISA test, expressed by a linear optical density (OD) scale. The blood samples of all participants were tested anonymously, and were scored under a code number. A test recording above 1.3 OD units was defined as positive.
Results: The PAA titers of schizophrenia patients (1.6 +/- 0.4 OD units, range: 0.7-2.3 OD units) were significantly higher than those of the control group (1.0 +/- 0.4 OD units, range: 0.4-1.8 OD units; p < 0.0001). In 61% of the young schizophrenic patients (22 out of the 36 patients), a positive result (OD >1.3 units) was recorded. In the control group, only 12.2% (6 of the 49 subjects) displayed a positive result (p < 0.0001).
Conclusions: These findings support further assessment of PAA titers as a potential biomarker for patients with clinical signs and symptoms of schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000235801 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study.
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Transdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance.
Neuropsychopharmacol Hung
December 2024
Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest.
Article Synopsis
- The study suggests that autism spectrum disorder and schizophrenia may share overlapping features, particularly regarding minimal self-experience, characterized by altered body ownership and agency.
- A literature review highlighted tools used to assess self-experience in both disorders, revealing that minimal self-disturbances are significant in both, though they manifest differently.
- The findings indicate that these disorders might be part of a shared psychopathological continuum, with common neural mechanisms contributing to self-disturbances across the conditions.
Borderline personality disorder and moral responsibility.
Med Health Care Philos
January 2025
Université de Genève, Genève, Switzerland.
This paper seeks to determine the extent to which individuals with borderline personality disorders can be held morally responsible for a particular subset of their actions: disproportionate anger, aggressions and displays of temper. The rationale for focusing on these aspects lies in their widespread acknowledgment in the literature and their plausible primary association with blame directed at BPD patients. BPD individuals are indeed typically perceived as "difficult patients" (Sulzer 2015:82; Bodner et al.
View Article and Find Full Text PDFDiagnosis of Schizophrenia and Its Subtypes Using MRI and Machine Learning.
Brain Behav
January 2025
Computational and Artificial Intelligence Department, Institute of Cognitive Science Studies, Tehran, Iran.
Purpose: The neurobiological heterogeneity present in schizophrenia remains poorly understood. This likely contributes to the limited success of existing treatments and the observed variability in treatment responses. Our objective was to employ magnetic resonance imaging (MRI) and machine learning (ML) algorithms to improve the classification of schizophrenia and its subtypes.
View Article and Find Full Text PDFOn the improvement of schizophrenia detection with optical coherence tomography data using deep neural networks and aggregation functions.
Sci Rep
December 2024
Department of Clinical Neuropsychiatry, Medical University of Lublin, ul. Głuska 1, 20-439, Lublin, Poland.
Schizophrenia is a serious mental disorder with a complex neurobiological background and a well-defined psychopathological picture. Despite many efforts, a definitive disease biomarker has still not been identified. One of the promising candidates for a disease-related biomarker could involve retinal morphology , given that the retina is a part of the central nervous system that is known to be affected in schizophrenia and related to multiple illness features.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!